guest ::
| Home > Publications database > Plasma Fibrinogen and sP-Selectin are associated with the risk of lung cancer in a prospective study. |
| Home > Publications database > Plasma Fibrinogen and sP-Selectin are associated with the risk of lung cancer in a prospective study. |
| Journal Article | DKFZ-2019-01314 |
; ; ; ; ; ; ; ; ; ;
2019
AACR
Philadelphia, Pa.
This record in other databases: 
Please use a persistent id in citations: doi:10.1158/1055-9965.EPI-18-1285
Abstract: While enhanced platelet activation and a procoagulant state may drive lung cancer progression and metastases, less is known about their role in earlier phases of cancer development. Thus, we evaluated whether pre-diagnostic biomarkers of platelet activation and coagulation are related to the risk of lung cancer in the prospective EPIC-Heidelberg Study using a case-cohort design.Levels of fibrinogen, soluble glycoprotein (sGP) IIb/IIIa, soluble P-selectin (sP-selectin), soluble thrombomodulin (sTM), and thrombopoietin (TPO) were measured in baseline plasma samples of a random subcohort (n=2,480) and incident cases of lung cancer (n=190). Multivariable-adjusted Cox proportional hazards regression analyses were used to obtain Hazard Ratios (HRs) of lung cancer across quartiles of biomarker levels.Fibrinogen (HR highest vs. lowest quartile: 1.91 [95 % confidence interval: 1.09, 3.34]) and sP-Selectin (HR: 2.51 [1.39, 4.52]) were significantly associated with lung cancer risk in multivariable adjusted Cox regression models. Adding both biomarkers to the established PLCOm2012 algorithm, which alone showed a C-statistic of 0.788, led to a slight increment in lung cancer risk prediction, with a C-statistic of 0.814.Our findings indicate that enhanced platelet activation and a pro-coagulative state contribute to lung carcinogenesis.The present prospective study supports the hypothesis of increased coagulation being a possible driver of lung carcinogenesis, as strong positive associations were found between two procoagulative markers, sP-Selectin and fibrinogen, with lung cancer risk. Both biomarkers could improve lung cancer risk prediction, but external validation of the results is needed.
; BIOSIS Previews ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; IF < 5 ; JCR ; NCBI Molecular Biology Database ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |